Previous Publications



Pancreatic Metastasectomy: an Analysis of Survival Outcomes and Prognostic Factors. Chua TC, Petrushnko W, Mittal A, Gill AJ, Samra JS. J Gastrointest Surg. 2016 Feb 18. [Epub ahead of print]
Immunoregulatory Forkhead Box Protein p3-Positive Lymphocytes Are Associated with Overall Survival in Patients with Pancreatic Neuroendocrine Tumors. de Reuver PR, Mehta S, Gill P, Andrici J, D’Urso L, Clarkson A, Mittal A, Hugh TJ, Samra JS, Gill AJ. J Am Coll Surg. 2016 Mar;222(3):281-7.
Transverse closure of mesenterico-portal vein after vein resection in pancreatoduodenectomy. Chua TC, de Reuver PR, Staerkle RF, Neale ML, Arena J, Mittal A, Shanbhag ST, Gill AJ, Samra JS. Eur J Surg Oncol. 2016 Feb;42(2):211-8.
Systematic Review and Meta-Analysis of Enucleation Versus Standardized Resection for Small Pancreatic Lesions. Chua, T., Yang, T., Gill, A., Samra, J. Annals of Surgical Oncology, 2016;23(2), 592-599.




Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, Simpson S, Mead S, Jones MD, Samra JS, Gill AJ, Watson N, Chin VT, Humphris JL, Chou A, Brown B, Morey A, Pajic M, Grimmond SM, Chang DK, Thomas D, Sebastian L, Sjoquist K, Yip S, Pavlakis N, Asghari R, Harvey S, Grimison P, Simes J, Biankin AV. Clinical Cancer Research 2015; 21:2029-37.
Extended pancreaticoduodenectomy as defined by the International Study Group for Pancreatic Surgery is associated with worse survival but not with increased morbidity. de Reuver PR, Mittal A, Neale M, Gill AJ, Samra JS. Surgery 2015; 158(1):183-90.
Distal pancreatectomy, splenectomy, and celiac axis resection (DPS-CAR): Common hepatic arterial stump pressure should determine the need for arterial reconstruction. Mittal A, de Reuver PR, Shanbhag S, Staerkle RF, Neale M, Thoo C, Hugh TJ, Gill AJ, Samra JS. Surgery 2015; 157(4):811-7.
Pathogenic PALB2 mutation in metastatic pancreatic neuroendocrine tumour: A case report. Chan D, Clarke S, Gill AJ, Chantrill L, Samra J, Li BT, Barnes T, Nahar K, Pavlakis N. Mol Clin Onc, 2015;3:817-819.
A patient-derived subrenal capsule xenograft model can predict response to adjuvant therapy for cancers in the head of the pancreas. Xue A, Julovi S, Hugh TJ, Samra JS, Wong MH, Gill AJ, Smith RC. Pancreatology Jul-Aug;15(4):397-404.
Efficacy of primary tumour volume as a predictor of survival compared with size alone in pancreatic ductal adenocarcinoma. Gundara J, Gill AJ, Samra J. Oncology Letters 2015;10(2):744-748.
Somatostatin receptor SSTR-2a expression is a stronger predictor for survival than Ki-67 in Pancreatic Neuroendocrine Tumours. Meytal S, de Reuver P, Gill P, Andrici J, D’Urso L, Mittal A, Pavlakis N, Clarke S, Samra JS, Gill AJ. Medicine 2015 Oct;94(40):e1281.
A Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Chandrasegaram MD, Goldstein D, Simes J, Gebski V, Kench JG, Gill AJ, Samra JS, Merrett ND, Richardson AJ, Barbour AP. British Journal of Surgery 2015; 102: 1459–1472
Endovascular stenting of mesenterico-portal vein stenosis to reduce blood flow through venous collaterals prior to pancreatoduodenectomy. Chua TC, Wang F, Maher R, Gananadha S, Mittal A, Samra JS. Langenbecks Arch Surg. 2015 Jul;400(5):629-31.




The clinical impact of early complete pancreatic head devascularisation during pancreatoduodenectomy. Gundara JS, Wang F, Alvarado-Bachmann R, Williams N, Choi J, Gananadha S, Gill AJ, Hugh TJ, Samra JS. American Journal of Surgery 2013; Oct;206(4):518-25.
Frozen section of the pancreatic neck margin in pancreatoduodenectomy for pancreatic adenocarcinoma is of limited utility. Pang TCY, Wilson O, Argueta MA, Hugh TH, Chou A, Samra JS, Gill AJ. Pathology 2014; 46(3):188-192.
Adverse tumour biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. Wang F, Gill AJ, Neale M, Puttswamy V, Gananadha S, Pavlakis N, Clarke SJ, Hugh TJ, Samra JS. Annals Surgical Oncology 2014; 21:1937-47.
Co-targeting of epidermal growth factor receptor (EGFR) and PI3K overcomes PI3K/Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Wong MH, Xue A, Julovi SM, Pavlakis N, Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC, Smith RC. Clinical Cancer Research 2014 Aug 1;20(15):4047-58.




The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events. Cummins M, Pavlakis N. Ther Adv Med Oncol. 2013 Sep;5(5):286-300.




Impact of Gemcitabine Chemotherapy and 3-Dimensional Conformal Radiation Therapy/5-Fluorouracil on Quality of Life of Patients Managed for Pancreatic Cancer. Short M, Goldstein D, Halkett G, Reece W, Borg M, Zissiadis Y, Kneebone A, Spry N. Int J Radiat Oncol Biol Phys. 2012 Apr 27.
Grafts for mesenterico-portal vein resections can be avoided during pancreatoduodenectomy. Wang F, Aranagam R, Gill AJ, Puttaswamy V, Neale M, Gananadhal S, Hugh TJ, Samra JS. Journal of the American College of Surgeons 2012; 215(4):569-79.
Serum Apolipoprotein C-II is Prognostic for Survival after Pancreatic Resection for Adenocarcinoma. Xue A, Chang JW, Chung L, Samra J, Hugh T, Gill AJ, Butturini G, Baxter RC, Smith RC. British Journal of Cancer 2012; 107(11):1883-91.




One hundred and seventy-eight consecutive pancreatoduodenectomies without mortality: role of the multidisciplinary approach. Samra JS, Bachmann RA, Choi J, Gill AJ, Neale M, Puttaswamy V, Bell C, Norton I, Cho S, Blome S, Maher R, Gananadha S, Hugh TJ. Hepatobiliary and Pancreatic Disease International 2011 Aug;10(4):415-21.
Multivisceral resection of pancreatic neuroendocrine tumours: a report of two cases. Gundara JS, Alvarado-Bachman R, Williams N, Gananadha S, Gill AJ, Hugh TJ, Samra JS. World Journal of Surgical Oncology 2011, 9:93





Management of advanced neuroendocrine tumors with hepatic metastasis. Khasraw M, Gill A, Harrington T, Pavlakis N, Modlin I. J Clin Gastroenterol. 2009 Oct;43(9):838-47.




Accrediting radiation technique in a multicentre trial of chemoradiation for pancreatic cancer.
Spry N, Bydder S, Harvey J, Borg M, Ngan S, Millar J, Graham P, Zissiadis Y, Kneebone A, Ebert M. J Med Imaging Radiat Oncol. 2008 Dec;52(6):598-604.




High expression of Plasminogen Activator Inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma. Smith R, Xue A, Gill A, Scareltt C, Saxby A, Clarkson A, Hugh T. World Journal of Surgery 2007 Mar;31(3):493-502
3D Radiotherapy Can Be Safely Combined with Sandwich Systemic Gemcitabine Chemotherapy in the Management of Pancreatic Cancer: Factors Influencing Outcome.
Spry N, Harvey J, Macleod C, Borg M, Ngan SY, Millar JL, Graham P, Zissiadis Y, Kneebone A, Carroll S, Davies T, Reece WH, Iacopetta B, Goldstein D. Int J Radiat Oncol Biol Phys. 2007 Dec 28.




Modified extended pancreaticoduodenectomy: En block resection of the peripancreatic retroperitoneal tissue and the head of pancreas. Samra JS, Gananadha S, Gill A, Smith RC Hugh TJ. Australian and New Zealand Journal of Surgery 2006, 76(11): 1017-1020